scholarly journals Liquid Biopsy perspectives theranostics and personalized oncology

2020 ◽  
pp. 073-077
Author(s):  
Ascencio Gonzalez C Daniel
Keyword(s):  
Liquid Biopsy ◽  
Personalized Oncology

scholarly journals Liquid Biopsy in Endometrial Cancer: New Opportunities for Personalized Oncology

2018 ◽  
Vol 19 (8) ◽  
pp. 2311 ◽  
Author(s):  
Laura Muinelo-Romay ◽  
Carlos Casas-Arozamena ◽  
Miguel Abal
Keyword(s):  
Endometrial Cancer ◽  
Liquid Biopsy ◽  
Personalised Medicine ◽  
Response To Therapy ◽  
Diagnostic Tools ◽  
Precision Oncology ◽  
Tumour Heterogeneity ◽  
Genomic Studies ◽  
Personalized Oncology ◽  
Circulating Tumour Dna

The identification of new molecular targets and biomarkers associated with high risk of recurrence and response to therapy represents one of the main clinical challenges in the management of advanced disease in endometrial cancer. In this sense, the field of liquid biopsy has emerged as a great revolution in oncology and is considered “the way” to reach personalised medicine. In this review, we discuss the promising but already relatively limited advances of liquid biopsy in endometrial cancer compared to other types of tumours like breast, colorectal or prostate cancer. We present recent data analysing circulating tumour material in minimally-invasive blood samples, but also in alternative forms of liquid biopsy like uterine aspirates. Proteomic and genomic studies focused on liquid-based uterine samples are resulting not only in optimal diagnostic tools but also in reliable approaches to address tumour heterogeneity. Likewise, circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) represent an opportunity for the correct stratification of patients, for the assessment of early recurrent disease or for the real-time monitoring of therapy responses. Appropriately designed studies and implementation in clinical trials will determine the value of liquid biopsy for precision oncology in endometrial cancer.

scholarly journals LIQUID BIOPSY: THERANOSTICS AND PERSONALIZED ONCOLOGY

2020 ◽  
pp. 5-6
Author(s):  
AKASH MALI ◽  
SHRAVNI GOSAVI ◽  
GOVIND SHUKLA
Keyword(s):  
Liquid Biopsy ◽  
Acquired Resistance ◽  
Modern Science ◽  
Genetic Alterations ◽  
Circulating Dna ◽  
Genomic Evolution ◽  
Circulating Free Dna ◽  
Biopsy Specimens ◽  
Genetic Landscape ◽  
Personalized Oncology

Cancer is linked with mutated genes, and the study of tumor-associated genetic alterations is gradually used for diagnostic and treatment purposes. The solid tumors are now obtained from biopsy and/or surgical or biopsy specimens. Tumor cells release circulating free DNA into the blood, but the majority of circulating DNA are often not of cancerous origin, and the detection of cancer-associated alleles in the blood has long been unbearable to achieve. Modern science has overwhelmed these restrictions, making it possible to identify both genetic and epigenetic aberrations. A liquid biopsy (LB) or blood sample can provide the genetic landscape of all cancerous lesions (primary and metastases) as well as offering the opportunity to systematically track genomic evolution. This communication will explore how LB is associated with personalized oncology to predict response to treatments and the development of acquired resistance.

TKI-Resistenzen beim EGFR-positiven NSCLC

2019 ◽  
Vol 10 (05) ◽  
pp. 216-216
Author(s):  
Susanne Krome
Keyword(s):  
Liquid Biopsy ◽  
Invasives Monitoring ◽  
Egfr Tki

EGFR-Tyrosinkinase-Inhibitoren (EGFR-TKI) haben zu einem Paradigmenwechsel in der Behandlungsstrategie für nicht-kleinzellige Bronchialkarzinome (NSCLC) geführt und gehören inzwischen zum Standard. Dabei ist es auch wichtig, primäre und erworbene Resistenzen zu überwinden. Eine aktuelle Studie mit 116 Patienten ergab unterschiedliche Resistenz-Mechanismen für TKI der 1./2. und der 3. Generation. Die Liquid Biopsy ist nach Ansicht der Autoren eine Option für ein nicht-invasives Monitoring der molekularen Veränderungen unter der EGFR-Therapie. Ein Review beschäftigte sich mit den Resistenzmechanismen und der Liquid Biopsy als Instrument für die Therapieplanung und -monitoring.

Liquid Biopsy bei Lungenkarzinom-Patienten – Untersuchungen zur Standardisierung der Präanalytik

Pneumologie ◽  
2018 ◽  
Vol 72 (S 01) ◽  
pp. S36-S36
Author(s):  
B Schmidt ◽  
B Wollschläger ◽  
I Reindl ◽  
N Lambrecht ◽  
S Eisenmann ◽  
...  
Keyword(s):  
Liquid Biopsy

NETest liquid biopsy is diagnostic of lung neuroendocrine tumors and identifies progressive disease

2018 ◽  
Author(s):  
Anna Malczewska ◽  
Beata Kos-Kudla ◽  
Pier-Luigi Filosso ◽  
Harry Aslanian ◽  
Anna Lewczuk ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Liquid Biopsy ◽  
Progressive Disease

A liquid biopsy for the diagnosis and monitoring of bronchopulmonary/lung carcinoid

2017 ◽  
Author(s):  
Irvin M Modlin ◽  
Mark Kidd ◽  
Ignat Drozdov ◽  
Harry Aslanian ◽  
Lisa Bodei ◽  
...  
Keyword(s):  
Liquid Biopsy ◽  
Lung Carcinoid

Human Saliva as a Liquid Biopsy for Detecting the SARS-CoV-2

2020 ◽  
Vol 29 (Special Supplement) ◽  
pp. S1-S3
Author(s):  
Zohaib Khurshid ◽  
◽  
Shahjahan Katpar ◽  
Keyword(s):  
Liquid Biopsy ◽  
Human Saliva
Sign in / Sign up

Export Citation Format

Share Document